Key result
Empagliflozin had a neutral impact on left ventricular global longitudinal strain (MD 0.53%) and peak oxygen uptake compared to sitagliptin in patients with type 2 diabetes and normal heart function.
Why the study?
The mechanisms by which SGLT2 inhibitors prevent heart failure and influence cardiac structure and function remain unclear.
Does empagliflozin improve myocardial contractility and cardiopulmonary fitness in subjects with type 2 diabetes without heart disease?
Comparison
Empagliflozin 10 mg vs sitagliptin 100 mg
Design
Randomized trial
Follow-up
6 months
Authors
Loading...
Neutral on LV-GLS and VO2peak in T2D with normal LV function; leaves open SGLT2i mechanisms in patients with subclinical dysfunction.
RCT (n=44)
Open-label
Randomized
No
Does empagliflozin improve myocardial contractility and cardiopulmonary fitness in subjects with type 2 diabetes without heart disease?
Mean Difference: 0.53 (95% CI -0.56–1.62)
Empagliflozin has a neutral impact on LV-GLS and exercise tolerance in T2D patients with normal LV function, though it may improve contractility in those with subclinical dysfunction.
Nesti et al. (2022) conducted an RCT in Type 2 diabetes without heart disease (n=44). Empagliflozin vs. Sitagliptin 100 mg was evaluated on Left ventricle global longitudinal strain (LV-GLS) at 6 months (MD 0.53%, 95% CI -0.56 to 1.62). Empagliflozin had a neutral impact on left ventricular global longitudinal strain (MD 0.53%) and peak oxygen uptake compared to sitagliptin in patients with type 2 diabetes and normal heart function.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: